The European Commission (EU) has granted Bristol-Myers Squibb’s Daklinza (daclatasvir) approval for an all-oral drug regimen for the treatment of four genotypes of chronic hepatitis C infection.
An investigational drug that researchers hope will reverse nerve damage in patients with multiple sclerosis (MS) has been found to be safe and well tolerated in early trials.
The big question is whether it will work, researchers said.
The US Food and Drug Administration announced it will give priority review status to Amgen’s application to market ivabradine as a treatment for chronic heart failure.
Clinicians who treat patients suffering with osteoarthritis pain have a new low-dose nonsteroidal anti-inflammatory drug (NSAID) option at their disposal. Zorvolex (diclofenac) was developed to meet prevailing FDA recommendations regarding NSAID dosing and treatment duration.
One-pill regiment includes abacavir, dolutegravir and lamivudine.
Eliquis is also now indicated for reducing the risk of recurrent DVT and PE following initial therapy.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
A new drug was given tentative approval by the US Food and Drug Administration to help patients with both type 1 and type 2 diabetes.
Fixed-dose tablet is the first sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin combo product to receive approval in the US.